Gilead Sciences Newswire
Comprehensive Real-Time News Feed for Gilead Sciences.
Results 1 - 20 of 803 in Gilead Sciences
-
Gilead Sciences's Neutral Rating Reaffirmed at Zacks
... issued reports about the stock. Analysts at Oppenheimer reiterated an "outperform" rating on shares of Gilead Sciences in a research note to investors on Monday. Separately, analysts at Argus upgraded shares of Gilead Sciences from a "hold" rating ... Comment?
-
NASDAQ Active Stock Watch List: MannKind Corp. (NASDAQ:MNKD) and...
Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding MannKind Corp. and Gilead Sciences Inc. . Comment?
-
Many different analysts have an opinion on the world's largest biotech Amgen , but how deep are they diving into the story? Amgen provides a nice blend of large cap value and growth, mixed with small cap growth through partnership deals. Comment?
-
... would have the money or insurance to pay for it. The only approved version in the U.S. is Truvada, made by Gilead Sciences Inc. It costs more than $14,000 a year. In Thailand, the tenofovir used in the study costs about $360. Truvada came on the ... Comment?
-
Gilead Sciences, Inc. to Present at the Healthcare Conference on Tuesday, June 18
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! FOSTER CITY, Calif.-- --Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston. Comment?
-
Wells Faro to host a conference
w/Photo
Check below for free stories on the last two weeks. Comment?
-
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston. Comment?
-
CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
... Mr. Caracciolo has been a Director at CytoDyn since December 2011. Mr. Caracciolo was formerly employed at Gilead Sciences, Inc. (Nasdaq: GILD), where he served as Senior Vice President, Manufacturing and Operations, and was a senior member of ... Comment?
-
Gilead Sciences to Present at the Wells Fargo Securities 2013...
)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston. John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer, will ... Comment?
-
Gilead Sciences Given Outperform Rating at Oppenheimer
... sales of ~$700M in NHL/CLL, but see the potential for meaningful upside. We reiterate Outperform." Shares of Gilead Sciences ( NASDAQ: GILD ) traded down 0.77% during mid-day trading on Monday, hitting $51.83. Gilead Sciences has a 52 week low of ... Comment?
-
Gilead Sciences, Inc. (GILD), American International Group, Inc....
w/Photo
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year. Comment?
-
Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following ...
In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating and $61.00 price target on Gilead Sciences . Comment?
-
Huge Upside on Pipeline Strength
... David's Supernova service. Mohsin Saeed has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all ... Comment?
-
Gilead's Idelalisib Shows Response in Refractory Indolent Non-Hodgkin's Lymphoma
Jun. 17, 2013-- Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib , an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Comment?
-
Gilead Sciences, Inc. Announces Interim Phase 2 Data for Idelalisib...
Gilead Sciences, Inc. Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin's Lymphoma Staying up-to-date has never been simpler. Comment?
-
Gilead Announces Interim Phase 2 Data fo ...
Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib , an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Comment?
-
Gilead Interim Phase 2 Data for Idelalisib Shows Response in...
Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib , an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Comment?
-
New Market Report Now Available: Colorectal Cancer - Pipeline Review, H1 2013
... Ltd., H1 2013 GlaxoSmithKline plc, H1 2013 Tekmira Pharmaceuticals Corp., H1 2013 Genentech, Inc., H1 2013 Gilead Sciences, Inc., H1 2013 Daiichi Sankyo Company, Ltd, H1 2013 Merck & Co., Inc., H1 2013 AbGenomics International, Inc., H1 2013 Oxford ... Comment?
-
The Biggest Companies That Don't Pay Dividends - But May Be About To
w/Photo
... for example, has barely budged since 2004). Yet you'll notice a pair of large biotechs on the table above, Gilead Sciences (Nasdaq: GILD ) and Celgene (Nasdaq: CELG ) . With each passing year, these companies are starting to resemble the Big Pharma ... Comment?
-
New Market Research Report: Gilead Sciences, Inc. (GILD) - Financial...
2013-06-14 18:25:16 - Fast Market Research recommends "Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review" from GlobalData, now available Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company. It carries out the ... Comment?
Gilead Sciences Forum
Most Popular
- Palin returns to Fox News praising Sen. Cruz - 143 comments
- House proposal to further criminalize illegal immigration criticized - 52 comments
- Labor group asks bishop to talk gay rights in the wake of teacher's firing - 163 comments
- Why the Supreme Court may not say ‘I do’ to gay marriage - 52 comments
- Video: Obama: US will meet Taliban ahead of Afghan-led peace process - 46 comments
- On Europe trip, Obama will face a continent frustrated by his actions and ina... - 60 comments
- Broad immigration reform will make our communities safer - 65 comments
- The Kaitlyn Hunt Case: Teenage Romance Or Sexual Predator? - 70 comments
- Chillicothe Police Officer Falls Asleep While Driving, Strikes 3 Vehicles - 19 comments
- Brazil congressional panel approves controversial bill that would allow 'gay ... - 18 comments
Copyright ©2013 Topix LLC
